Kamel Ehab M, Thumshirn Miriam, Truninger Kaspar, Schiesser Marc, Fried Michael, Padberg Barbara, Schneiter Didier, Stoeckli Sandro J, von Schulthess Gustav K, Stumpe Katrin D M
Nuclear Medicine, Department of Medical Radiology, University Hospital of Zurich, CH-8091 Zurich, Switzerland.
J Nucl Med. 2004 Nov;45(11):1804-10.
This study was undertaken to identify the clinical value of incidentally detected lesions (IDLs) in the gastrointestinal tract (GIT) with (18)F-FDG PET/CT.
The reported database of 3,281 patients who underwent partial-body (18)F-FDG PET/CT scans from April 2001 to September 2003 was reviewed. Patients with incidental (18)F-FDG accumulations in the GIT that were associated with concomitant abnormal soft-tissue density or wall thickening on the native CT were evaluated. Incidental PET/CT findings were correlated with endoscopic and histopathologic results.
According to our selection criteria, 98 (3%) of the 3,281 patients had an IDL of the GIT on (18)F-FDG PET/CT. Correlative endoscopic findings were available in 69 (70%) of 98 patients. Of these, 13 patients (19%) were harboring newly occurring cancers of the GIT in addition to preexisting aerodigestive tract tumors (n = 12) and malignant melanoma (n = 1). Twenty-nine (42%) patients were identified with precancerous lesions, such as advanced colonic adenomas (n = 27), Barrett's esophagus (n = 1), and intestinal metaplasia of the gastric mucosa (n = 1). Inflammatory and other benign GIT lesions were detected in 12 (17%) and 6 (8%) patients, respectively. In 9 (13%) patients, PET/CT was false-positive, showing normal findings in subsequent endoscopic examinations. In 20 (28%) of 69 patients, PET/CT findings had a relevant impact on the clinical management. Twenty-nine (30%) of the 98 patients were not subject to a further endoscopic examination because of the extent and nature of the primary tumor (n = 17), loss to follow-up (n = 7), death shortly after PET (n = 3), and patient unwillingness (n = 2).
Although IDLs of the GIT on (18)F-FDG PET/CT scans are found only in about 3% of cases, they are associated with a substantial risk of an underlying cancerous or precancerous lesion. Early identification of these occult lesions may have a major impact on the patients' management and outcome.
本研究旨在通过[¹⁸F] - FDG PET/CT确定胃肠道(GIT)中偶然发现病变(IDL)的临床价值。
回顾了2001年4月至2003年9月期间接受局部[¹⁸F] - FDG PET/CT扫描的3281例患者的报告数据库。对GIT中伴有[¹⁸F] - FDG偶然积聚且在原始CT上伴有异常软组织密度或肠壁增厚的患者进行评估。将PET/CT偶然发现的结果与内镜和组织病理学结果进行关联。
根据我们的选择标准,3281例患者中有98例(3%)在[¹⁸F] - FDG PET/CT上发现GIT的IDL。98例患者中有69例(70%)可获得相关的内镜检查结果。其中,除了原有的气消化道肿瘤(n = 12)和恶性黑色素瘤(n = 1)外,13例患者(19%)患有新发生的GIT癌症。29例(42%)患者被发现患有癌前病变,如晚期结肠腺瘤(n = 27)、巴雷特食管(n = 1)和胃黏膜肠化生(n = 1)。分别在12例(17%)和6例(8%)患者中检测到炎症性和其他良性GIT病变。9例(13%)患者PET/CT出现假阳性,后续内镜检查显示正常结果。69例患者中有20例(28%),PET/CT结果对临床管理有相关影响。98例患者中有29例(30%)由于原发肿瘤的范围和性质(n = 17)、失访(n = 7)、PET后不久死亡(n = 3)以及患者不愿意(n = 2)而未接受进一步的内镜检查。
尽管在[¹⁸F] - FDG PET/CT扫描中GIT的IDL仅在约3%的病例中发现,但它们与潜在的癌性或癌前病变的重大风险相关。早期识别这些隐匿性病变可能对患者的管理和预后产生重大影响。